13F Holdings
中文EN

PVCT PROVECTUS BIOPHARMACEUTICALS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 315545 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.5%
TTM net income YoY-14.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-30.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,575.3%
Net margin-1,615.8%
FCF margin—
EBITDA margin-1,574.8%

Returns

ROE—
ROA-637.5%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets1,003.6%
Debt / equity—
Current ratio0.08x
Interest coverage-991.90x

Cash quality & payout

Operating cash flow / net income0.61x
Accruals ratio-247.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$336,108$617,140$557,710$989,042—
R&D expense$1.90M$2.05M$1.75M$2.39M$2.61M
SG&A expense$3.73M$3.10M$1.71M$2.03M$2.06M
Operating income-$5.29M-$4.53M-$2.90M-$3.43M-$4.67M
Interest expense$5,338$13,591$5,650$3,409$961,702
Pretax income-$5.51M-$4.77M-$3.10M-$3.55M-$5.54M
Net income-$5.43M-$4.73M-$3.10M-$3.55M-$5.54M
EBITDA-$5.29M-$4.53M-$2.89M-$3.42M-$4.66M
EPS (basic)-0.01-0.01-0.01-0.01-0.01
EPS (diluted)-0.01-0.01-0.01-0.01-0.01
Weighted avg. shares (diluted)420.28M419.81M419.51M419.47M408.22M
Banking
Net interest income-$210,359-$239,073-$216,214-$163,691-$961,698
Balance sheet
Cash & equivalents$251,291$307,442$76,576$21,605$682,984
Receivables——$476$394$5,107
Current assets$567,874$976,772$1.36M$1.90M$3.44M
PP&E, net$3,000$4,863$12,020$20,941$31,836
Total assets$697,502$1.01M$1.45M$2.04M$3.51M
Current liabilities$6.90M$6.98M$9.02M$8.19M$7.70M
Total liabilities$7.00M$6.98M$9.04M$8.27M$7.70M
Shareholders' equity-$6.30M-$5.96M-$7.59M-$6.23M-$4.19M
Shares outstanding420.28M420.28M419.52M419.45M419.45M
Cash flow statement
Operating cash flow-$3.33M-$3.28M-$2.57M-$3.04M-$1.01M
Financing cash flow$3.09M$2.75M$2.19M$1.37M$4.02M
Depreciation & amortization$1,863$7,157$8,921$10,895$12,865
Stock-based compensation$1.24M$1.28M$2,850$3,025$23,688

Free plan shows the latest 5 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.